Back to News
Market Impact: 0.15
Genprex Announces Research Identifying TROP2 Expression as Potential Biomarker for REQORSA Response
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
Genprex said new research identifying TROP2 expression as a potential predictive biomarker of response to its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), will be presented at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The article excerpt gives no study results or clinical efficacy figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
GNPX0.55
More News
- What Wall Street billionaires are saying about Democrats' midterm sweep
- A blue wave sends futures into the green
- Asian chip stocks slide as disappointing Qualcomm, Arm earnings weigh
- China Blocks SoftBank Acquisition of ABB Robot Unit, FT Says
- After the midterms, a bigger clash over data centers could be coming
- Inside the chip talent war: Trade secrets and rising Chinese rivals